Glutamine‐fueled mitochondrial metabolism is decoupled from glycolysis in melanoma

In this perspective, we revise the historic notion that cancer is a disease of mitochondria. We summarize recent findings on the function and rewiring of central carbon metabolism in melanoma. Metabolic profiling studies using stable isotope tracers show that glycolysis is decoupled from the tricarboxylic acid (TCA) cycle. This decoupling is not ‘dysfunction’ but rather an alternate wiring required by tumor cells to remain metabolically versatile. In large part, this requirement is met by glutamine feeding the TCA cycle as an alternative source of carbon. Glutamine is also used in non‐conventional ways, like traveling in reverse through the TCA flux to feed fatty acid biosynthesis. Biosynthetic networks linked with non‐essential amino acids alanine, serine, arginine, and proline are also significantly impacted by the use of glutamine as an alternate carbon source.

[1]  A. Scott,et al.  Role of nuclear medicine in the management of cutaneous malignant melanoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[3]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[4]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[5]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[6]  Jianrong Lu,et al.  Regulation of Glycolysis and the Warburg Effect by Estrogen-related Receptors , 2012, Oncogene.

[7]  A. Vercesi,et al.  Visualizing inhibition of fatty acid synthase through mass spectrometric analysis of mitochondria from melanoma cells. , 2011, Rapid communications in mass spectrometry : RCM.

[8]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[9]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[10]  F. Izzo,et al.  Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. , 2011, Oncology reports.

[11]  Hui-Kuan Lin,et al.  Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.

[12]  R. Deberardinis,et al.  Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. , 2009, Cancer research.

[13]  Jesse M. Platt,et al.  Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability , 2011, Proceedings of the National Academy of Sciences.

[14]  Elizabeth L. Johnson,et al.  Quiescent Fibroblasts Exhibit High Metabolic Activity , 2010, PLoS biology.

[15]  L. Cantley,et al.  PHGDH amplification and altered glucose metabolism in human melanoma , 2011, Pigment cell & melanoma research.

[16]  Andrei L Osterman,et al.  Comparative Metabolic Flux Profiling of Melanoma Cell Lines , 2011, The Journal of Biological Chemistry.

[17]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[18]  R. Rodenburg,et al.  Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. , 2007, The Journal of clinical investigation.

[19]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[20]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[21]  A. Lane,et al.  Targeting aspartate aminotransferase in breast cancer , 2008, Breast Cancer Research.

[22]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[23]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[24]  R. Deberardinis,et al.  Pyruvate carboxylase is required for glutamine-independent growth of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[25]  T. Shibata,et al.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.

[26]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[27]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[28]  B. Delage,et al.  Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer , 2010, International journal of cancer.

[29]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[30]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[31]  E. Fosslien.  Cancer morphogenesis: role of mitochondrial failure. , 2008, Annals of clinical and laboratory science.

[32]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[33]  Jeffrey W. Smith,et al.  Profiling of central metabolism in human cancer cells by two-dimensional NMR, GC-MS analysis, and isotopomer modeling , 2008, Metabolomics.

[34]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[35]  Chen Yang,et al.  Comparative Metabolomics of Breast Cancer , 2006, Pacific Symposium on Biocomputing.

[36]  R. McLendon,et al.  IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. , 2010, Biochemical and biophysical research communications.

[37]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[38]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[39]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[40]  Fabian V. Filipp,et al.  Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells , 2012, Pigment cell & melanoma research.

[41]  M. Loda,et al.  Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model , 2008, International journal of cancer.

[42]  Adam D. Richardson,et al.  Central carbon metabolism in the progression of mammary carcinoma , 2007, Breast Cancer Research and Treatment.

[43]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .